Residual sleep disturbance and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine

被引：0
|
作者：
Huaiyu Yang
Lara Sinicropi-Yao
Sarah Chuzi
Soo Jeong Youn
Alisabet Clain
Lee Baer
Ying Chen
Patrick J McGrath
Maurizio Fava
George I Papakostas
机构：
[1] Harvard Medical School,Depression Clinical and Research Program, Massachusetts General Hospital
[2] Columbia University,Depression Evaluation Service Center, New York State Psychiatric Institute
来源：
Annals of General Psychiatry | / 9卷
关键词：
Major Depressive Disorder; Fluoxetine; Major Depressive Disorder; Hamilton Depression Rate Scale; Residual Symptom;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Plasma levels of interleukin-6 and selective serotonin reuptake inhibitor response in patients with major depressive disorder
    Yoshimura, Reiji
    Hori, Hikaru
    Ikenouchi-Sugita, Atsuko
    Umene-Nakano, Wakako
    Katsuki, Asuka
    Atake, Kiyokazu
    Nakamura, Jun
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2013, 28 (05) : 466 - 470
  • [42] Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder - A preliminary study
    George, Tony P.
    Sacco, Kristi A.
    Vessicchio, Jennifer C.
    Weinberger, Andrea H.
    Shytle, R. Douglas
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2008, 28 (03) : 340 - 344
  • [43] Diminished functional properties of T regulatory cells in major depressive disorder: The influence of selective serotonin reuptake inhibitor
    Jahangard, Leila
    Behzad, Mahdi
    JOURNAL OF NEUROIMMUNOLOGY, 2020, 344
  • [44] Neurocognitive Predictors of Clinical Improvement in Selective Serotonin Reuptake Inhibitor-Treated Adolescents with Major Depressive Disorder
    Maalouf, Fadi
    Bakhti, Rinad
    Tamim, Hani
    Shehab, Safa
    Brent, David
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2018, 28 (06) : 387 - 394
  • [45] Response to a Selective Serotonin Reuptake Inhibitor (Citalopram) in Major Depressive Disorder With Melancholic Features: A STAR*D Report
    McGrath, Patrick J.
    Khan, Ahsan Y.
    Trivedi, Madhukar H.
    Stewart, Jonathan W.
    Morris, David W.
    Wisniewski, Stephen R.
    Miyahara, Sachiko
    Nierenberg, Andrew A.
    Fava, Maurizio
    Rush, A. John
    JOURNAL OF CLINICAL PSYCHIATRY, 2008, 69 (12) : 1847 - 1855
  • [46] Role of serotonin transporter and receptor gene polymorphisms in treatment response to selective serotonin reuptake inhibitors in major depressive disorder
    Ramesh, Varsha
    Venkatesan, Vettriselvi
    Ramasamy, Balakrishnan
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2022, 37 (04)
  • [47] A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder
    Papakostas, George I.
    Fava, Maurizio
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2006, 51 (12): : 783 - 790
  • [48] Associations of childhood trauma with remission and treatment response after 12 weeks of selective serotonin reuptake inhibitor treatment in patients with major depressive disorder
    Li, Yanzhi
    Chen, Yan
    Jiang, Yingchen
    Wang, Wanxin
    Guo, Lan
    Fan, Beifang
    Liu, Yifeng
    Zhang, Huimin
    Lin, Xinyi
    Teopiz, Kayla M.
    Mcintyre, Roger S.
    Lu, Ciyong
    Han, Xue
    GENERAL HOSPITAL PSYCHIATRY, 2025, 92 : 12 - 19
  • [49] Treatment of major depressive disorder in children and adolescents - Most selective serotonin reuptake inhibitors are no longer recommended
    Ramchandani, P
    BRITISH MEDICAL JOURNAL, 2004, 328 (7430): : 3 - 4
  • [50] Resolution of sleepiness and fatigue in the treatment of major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors
    Papakostas, GI
    Nutt, DJ
    Tucker, VL
    Krishen, A
    Fava, M
    NEUROPSYCHOPHARMACOLOGY, 2005, 30 : S186 - S187
12345